Merck is striking back against the NEJM. “A current editor and former editor of the New England Journal of Medicine, which last month criticized drug maker Merck & Co. for withholding data from a published study on its withdrawn painkiller Vioxx, will be grilled next week by the company’s lawyers.
The depositions, ahead of the next round of product liability trials over Merck’s former blockbuster arthritis pill, will be held next Tuesday and Wednesday, Paul Shaw, an attorney representing the editors, said Wednesday.”
This is Merck’s definant response to NEJM’s editorial designed to protect themselves from future liability.
